Literature DB >> 29600390

Supervised versus unsupervised technology-based levodopa monitoring in Parkinson's disease: an intrasubject comparison.

Giovanna Lopane1, Sabato Mellone2, Mattia Corzani2, Lorenzo Chiari2,3, Pietro Cortelli1,4, Giovanna Calandra-Buonaura1,4, Manuela Contin5,6.   

Abstract

We aimed to assess the intrasubject reproducibility of a technology-based levodopa (LD) therapeutic monitoring protocol administered in supervised versus unsupervised conditions in patients with Parkinson's disease (PD). The study design was pilot, intrasubject, single center, open and prospective. Twenty patients were recruited. Patients performed a standardized monitoring protocol instrumented by an ad hoc embedded platform after their usual first morning LD dose in two different randomized ambulatory sessions: one under a physician's supervision, the other self-administered. The protocol is made up of serial motor and non-motor tests, including alternate finger tapping, Timed Up and Go test, and measurement of blood pressure. Primary motor outcomes included comparisons of intrasubject LD subacute motor response patterns over the 3-h test in the two experimental conditions. Secondary outcomes were the number of intrasession serial test repetitions due to technical or handling errors and patients' satisfaction with the unsupervised LD monitoring protocol. Intrasubject LD motor response patterns were concordant between the two study sessions in all patients but one. Platform handling problems averaged 4% of total planned serial tests for both sessions. Ninety-five percent of patients were satisfied with the self-administered LD monitoring protocol. To our knowledge, this study is the first to explore the potential of unsupervised technology-based objective motor and non-motor tasks to monitor subacute LD dosing effects in PD patients. The results are promising for future telemedicine applications.

Entities:  

Keywords:  Alternate finger tapping test; Information and communication technology; Levodopa; Parkinson’s disease; Therapeutic drug monitoring; Timed Up and Go test

Mesh:

Substances:

Year:  2018        PMID: 29600390     DOI: 10.1007/s00415-018-8848-1

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  26 in total

1.  Response to a standard oral levodopa test in parkinsonian patients with and without motor fluctuations.

Authors:  M Contin; R Riva; P Martinelli; G Procaccianti; P Cortelli; P Avoni; A Baruzzi
Journal:  Clin Neuropharmacol       Date:  1990-02       Impact factor: 1.592

2.  Dyskinesia detection and monitoring by a single sensor in patients with Parkinson's disease.

Authors:  Giovanna Lopane; Sabato Mellone; Lorenzo Chiari; Pietro Cortelli; Giovanna Calandra-Buonaura; Manuela Contin
Journal:  Mov Disord       Date:  2015-07-14       Impact factor: 10.338

3.  Body-worn sensors--the brave new world of clinical measurement?

Authors:  Walter Maetzler; Lynn Rochester
Journal:  Mov Disord       Date:  2015-07-14       Impact factor: 10.338

4.  Detecting and monitoring the symptoms of Parkinson's disease using smartphones: A pilot study.

Authors:  S Arora; V Venkataraman; A Zhan; S Donohue; K M Biglan; E R Dorsey; M A Little
Journal:  Parkinsonism Relat Disord       Date:  2015-03-07       Impact factor: 4.891

5.  Initiating dopaminergic treatment in Parkinson's disease.

Authors:  Anthony E Lang; Connie Marras
Journal:  Lancet       Date:  2014-06-11       Impact factor: 79.321

Review 6.  A clinical view on the development of technology-based tools in managing Parkinson's disease.

Authors:  Walter Maetzler; Jochen Klucken; Malcolm Horne
Journal:  Mov Disord       Date:  2016-06-07       Impact factor: 10.338

7.  Quantitative measurements of alternating finger tapping in Parkinson's disease correlate with UPDRS motor disability and reveal the improvement in fine motor control from medication and deep brain stimulation.

Authors:  Ana Lisa Taylor Tavares; Gregory S X E Jefferis; Mandy Koop; Bruce C Hill; Trevor Hastie; Gary Heit; Helen M Bronte-Stewart
Journal:  Mov Disord       Date:  2005-10       Impact factor: 10.338

Review 8.  When do levodopa motor fluctuations first appear in Parkinson's disease?

Authors:  Fabrizio Stocchi; Peter Jenner; Jose A Obeso
Journal:  Eur Neurol       Date:  2010-03-24       Impact factor: 1.710

9.  Clinical rating of dyskinesias in Parkinson's disease: use and reliability of a new rating scale.

Authors:  P Hagell; H Widner
Journal:  Mov Disord       Date:  1999-05       Impact factor: 10.338

Review 10.  Integration of technology-based outcome measures in clinical trials of Parkinson and other neurodegenerative diseases.

Authors:  Carlo Alberto Artusi; Murli Mishra; Patricia Latimer; Joaquin A Vizcarra; Leonardo Lopiano; Walter Maetzler; Aristide Merola; Alberto J Espay
Journal:  Parkinsonism Relat Disord       Date:  2017-07-26       Impact factor: 4.891

View more
  3 in total

1.  Quantitative Assessment of Motor Response to a Low Subacute Levodopa Dose in the Differential Diagnosis of Parkinsonisms at Disease Onset: Data from the BoProPark Cohort.

Authors:  Manuela Contin; Giovanna Lopane; Pietro Cortelli; Luisa Sambati; Susan Mohamed; Giovanna Calandra-Buonaura
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

Review 2.  Digital Technology in Movement Disorders: Updates, Applications, and Challenges.

Authors:  Jamie L Adams; Karlo J Lizarraga; Emma M Waddell; Taylor L Myers; Stella Jensen-Roberts; Joseph S Modica; Ruth B Schneider
Journal:  Curr Neurol Neurosci Rep       Date:  2021-03-03       Impact factor: 6.030

3.  Levodopa improves handwriting and instrumental tasks in previously treated patients with Parkinson's disease.

Authors:  Thomas Müller; Ali Harati
Journal:  J Neural Transm (Vienna)       Date:  2020-08-19       Impact factor: 3.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.